WALTHAM, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced participation in the following investor conferences: Dr.

WALTHAM, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors.

MORF-057 phase 1 safety, receptor occupancy, PK and mechanistic measures exceeded objectives; phase 2 program expected to begin 1Q22 Presented positive preclinical data from αvβ8 program at AACR Annual Meeting demonstrating anti-tumor activity in checkpoint refractory cancer models Announced

MORF-057 well tolerated across all phase 1 cohorts Dose-dependent α4β7 receptor occupancy (RO) observed with receptor saturation at 100 mg dose Biomarker changes including lymphocyte subset migration and CCR9 transcript levels provide early proof of biology Conference call today at 8:00 AM ET

Call to discuss positive results from Phase 1 trial of MORF-057 to be presented at ECCO 2021 Virtual Congress WALTHAM, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of

Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens well-tolerated across Phase 1 High receptor occupancy (RO) in Phase 1 SAD study confirmed by MAD results

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to present

Expanded research and development collaboration with Janssen for third integrin program Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 Received acceptance to present full MORF-057 Phase 1 data set at the ECCO’21 Virtual Congress in July Completed $245 million

Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to its

First data from oral αvβ8 program demonstrate potent anti-tumor response through TGFβ pathway Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and induced a lasting anti-tumor effect WALTHAM, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Morphic